Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Annual Report · 10-K

Edgewise Therapeutics, Inc.

EWTXNASDAQEQUITYCurrent

Annual Report

Filed Mar 3, 2025Accepted Mar 3, 2025, 8:05 AM ESTCIK 1710072Accession 0001558370-25-002006
Share

Company context

Edgewise Therapeutics is a leading biopharmaceutical company focused on novel, muscle-targeted therapeutics. Leveraging its expertise in muscle biology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardiometabolic conditions. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn, X, Facebook and Instagram.

Current securities

Recent company filings

  1. 4/A filingAug 17, 2026
  2. 4/A filingAug 17, 2026
  3. 4/A filingAug 17, 2026
  4. 4 filingAug 14, 2026
  5. 4 filingAug 14, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗